rufinamide (banzel) Report issue

Small molecule Orphan Drug FDA Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Rufinamide is an anti-epileptic drug that is FDA approved for the treatment of lennox-gastaut syndrome (LGS). The principal mechanism of action of rufinamide is modulation of the activity of sodium channels and, in particular, prolongation of the inactive state of the channel. Hormonal contraceptives may be less effective with rufinamide. Patients on valproate should begin at a rufinamide dose lower than 10 mg/kg per day (pediatric patients) or 400 mg per day (adults). Common adverse reactions include headache, dizziness, fatigue, somnolence, and nausea.   NCATS

Chemistry

  • SMILES: NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1
  • InChIKey: POGQSBRIGCQNEG-UHFFFAOYSA-N
  • Mol. Mass: 238.1935
  • ALogP: 0.7
  • ChEMBL Molecule:
    rufinamide  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$2.3070 - $1377.2500
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide | 1h-1,2,3-triazole-4-carboxamide, 1-((2,6-difluorophenyl)methyl)- | 60231/4 | banzel | cgp 33101 | cgp-33101 | e2080 | inovelon | ruf-331 | rufinamide | syn111 | xilep

Organizations (21)

Research & Development (9)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (2)


 

Epilepsy

Lennox Gastaut Syndrome

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Anxiety Disorders (Phase 2)

Drug Resistant Epilepsy (Phase 4)

Epilepsy ()

Glioma (Phase 4)

Healthy Volunteers (Phase 4)

Lennox Gastaut Syndrome ()

Pain (Phase 2)

Peripheral Nerve Injuries (Phase 2)

Seizures (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 11
  • # of Trial Organizations: 9

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue